Last checked at 17 Oct 2022 13:27
Allergy Therapeutics plc
("Allergy Therapeutics", "ATL", the "Company" or the "Group")
Result of GM
17 October 2022 Allergy Therapeutics (AIM: AGY), the fully integrated specialty pharmaceutical company specialising in allergy immunotherapy, announces that at the General Meeting ("GM") held today all resolutions were duly passed.
Accordingly, the Company has conditionally raised total gross proceeds of approximately £17,000,000 million in aggregate (before expenses) through the Subscription and Debt Financing as described in the announcement date 29 September 2022. The Subscription and Debt Financing remain conditional on Admission.
Admission
An application has been made for 35,000,000 New Ordinary Shares to be admitted to trading on AIM. Admission of the New Ordinary Shares are expected to occur at 8.00 a.m. on, or around, 19 October 2022. The New Ordinary Shares will rank pari passu with the Existing Ordinary Shares.
Total Voting Rights
Following Admission of the New Ordinary Shares, the Company's issued ordinary share capital will consist of 679,104,621 Ordinary Shares, carrying one vote each. The Company does not currently hold any shares in treasury. Therefore, the total number of voting rights in the Company following Admission will be 679,104,621. Shareholders may use this figure as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the issued share capital of the Company, under the FCA's Disclosure Guidance and Transparency Rules.
Save as defined herein, capitalised terms have the same meaning as in the Company's Subscription and Debt Financing announcement made by the Company on 29 September 2022.
- ENDS -
For further information, please contact:
Allergy Therapeutics
+44 (0) 1903 845 820
Manuel Llobet, Chief Executive Officer
Nick Wykeman, Chief Financial Officer
Panmure Gordon (Nominated Adviser and Broker)
+44 (0) 20 7886 2500
Freddy Crossley, Emma Earl, Corporate Finance
Rupert Dearden, Corporate Broking
Consilium Strategic Communications
+44 20 3709 5700
Mary-Jane Elliott / David Daley / Davide Salvi
allergytherapeutics@consilium-comms.com
Stern Investor Relations, Inc.
+1 212 362 1200
Christina Tartaglia
christina@sternir.com
Notes for editors:
About Allergy Therapeutics
Allergy Therapeutics is an international commercial biotechnology company focussed on the treatment and diagnosis of allergic disorders, including aluminium free immunotherapy vaccines that have the potential to cure disease. The Group sells proprietary and third-party products from its subsidiaries in nine major European countries and via distribution agreements in an additional ten countries. Its broad pipeline of products in clinical development includes vaccines for grass, tree and house dust mite, and peanut allergy vaccine in pre-clinical development. Adjuvant systems to boost performance of vaccines outside allergy are also in development.
Formed in 1999 out of Smith Kline Beecham, Allergy Therapeutics is headquartered in Worthing, UK with more than 11,000m2 of state-of-the-art MHRA-approved manufacturing facilities and laboratories. The Group, which employs c.600 employees, is listed on the London Stock Exchange (AIM:AGY). For more information, please see www.allergytherapeutics.com.